The FDA approved a new 300 mg/2 mL dose of Celltrion’s omalizumab biosimilar, Omlyclo, for the treatment of four allergic and ...
FDA approves Rybrevant Faspro, a subcutaneous amivantamab formulation, for all indications previously held by the intravenous formulation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback